Artemether-Lumefantrine Treatment Selects Plasmodium falciparum Multidrug Resistance 1 (pfmdr1) Increased Copy Number Among African Malaria Infections

Cláudia Fançony; Elsa Fortes-Gabriel; Félix Zage; Evangelia Alexiou; Ioanna Broumou; Leyre Pernaute-Lau; Jorge Panzo; Esperança J António; Mario S Cristovão; José M Domingos; Estevão Sassoma; Fernando Kuatoko; Edite Rosário; A. Martins; Anna Färnert; Luís Bernardino; Taís Nóbrega de Sousa; José Pedro Gil

doi:10.1093/infdis/jiaf155

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Our study suggests pfmdr1×N as a marker of P. falciparum in vivo response to lumefantrine in Africa, while indicating patients carrying infections with a pretreatment pfmdr1×N score ≥1.4 before treatment are a group experiencing decreased artemether-lumefantrine performance.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fançony et al. (2025) studied this question.

synapsesocial.com/papers/69dee04d5e217d93a5558d65 https://doi.org/10.1093/infdis/jiaf155

View Full Paper

Ask AI

Bookmark

Share

Artemether-Lumefantrine Treatment Selects Plasmodium falciparum Multidrug Resistance 1 (pfmdr1) Increased Copy Number Among African Malaria Infections

Ask about this paper

Abstract

Discussion

Cite This Study

Artemether-Lumefantrine Treatment Selects Plasmodium falciparum Multidrug Resistance 1 (pfmdr1) Increased Copy Number Among African Malaria Infections

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading